Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,081 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2.
Llibre JM, López Cortés LF, Aylott A, Wynne B, Matthews J, Van Solingen-Ristea R, Vandermeulen K, van Wyk J, Kahl LP. Llibre JM, et al. Among authors: matthews j. J Acquir Immune Defic Syndr. 2022 Sep 1;91(1):73-78. doi: 10.1097/QAI.0000000000003019. Epub 2022 May 11. J Acquir Immune Defic Syndr. 2022. PMID: 35551149 Free PMC article. Clinical Trial.
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Aboud M, Orkin C, Podzamczer D, Bogner JR, Baker D, Khuong-Josses MA, Parks D, Angelis K, Kahl LP, Blair EA, Adkison K, Underwood M, Matthews JE, Wynne B, Vandermeulen K, Gartland M, Smith K. Aboud M, et al. Lancet HIV. 2019 Sep;6(9):e576-e587. doi: 10.1016/S2352-3018(19)30149-3. Epub 2019 Jul 12. Lancet HIV. 2019. PMID: 31307948 Clinical Trial.
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
van Wyk J, Orkin C, Rubio R, Bogner J, Baker D, Khuong-Josses MA, Parks D, Angelis K, Kahl LP, Matthews J, Wang R, Underwood M, Wynne B, Nascimento MC, Vandermeulen K, Gartland M, Smith KY. van Wyk J, et al. Among authors: matthews j. J Acquir Immune Defic Syndr. 2020 Nov 1;85(3):325-330. doi: 10.1097/QAI.0000000000002449. J Acquir Immune Defic Syndr. 2020. PMID: 32675772 Free PMC article. Clinical Trial.
Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV.
Rolle CP, Berhe M, Singh T, Ortiz R, Wurapa A, Ramgopal M, Leone PA, Matthews JE, Dalessandro M, Underwood MR, Angelis K, Wynne BR, Merrill D, Nguyen C, van Wyk J, Zolopa AR. Rolle CP, et al. Among authors: matthews je. AIDS. 2021 Oct 1;35(12):1957-1965. doi: 10.1097/QAD.0000000000002979. AIDS. 2021. PMID: 34115650 Free PMC article. Clinical Trial.
Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two-drug regimen in SWORD-1/-2 phase 3 studies.
Mehta R, Lagishetty CV, Angelis K, Aylott A, Kahl L, Blair L, Matthews J, Wynne B, Crauwels H, Underwood M, Adkison KK. Mehta R, et al. Among authors: matthews j. Br J Clin Pharmacol. 2023 Jul;89(7):2190-2200. doi: 10.1111/bcp.15683. Epub 2023 Mar 1. Br J Clin Pharmacol. 2023. PMID: 36740580 Free article. Clinical Trial.
Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.
Rolle CP, Berhe M, Singh T, Ortiz R, Wurapa A, Ramgopal M, Jayaweera DT, Leone PA, Matthews JE, Cupo M, Underwood MR, Angelis K, Wynne BR, Merrill D, Nguyen C, van Wyk J, Zolopa AR. Rolle CP, et al. Among authors: matthews je. Open Forum Infect Dis. 2023 Mar 1;10(3):ofad101. doi: 10.1093/ofid/ofad101. eCollection 2023 Mar. Open Forum Infect Dis. 2023. PMID: 36968959 Free PMC article.
The Murtupuni Statement on rural generalist professional practice in Australia.
Hays RB, Barker RN, Cairns A, Sparke VL, Stewart RA, Varela S, Collins BE, Maloney C, Omond R, Sen Gupta T, Chalmers S, Chong HS, McKenna K, Forrest K, West E, Matthews J, Ballard R, Sabatino G, Turvey J, Symons J, Quabba A, Brown J. Hays RB, et al. Among authors: matthews j. Rural Remote Health. 2024 Nov;24(4):9308. doi: 10.22605/RRH9308. Epub 2024 Nov 6. Rural Remote Health. 2024. PMID: 39500560 Free article. No abstract available.
Use of immunomodulatory treatment for non-infectious uveitis: an International Ocular Inflammation Society report of real-world practice.
Branford JA, Bodaghi B, Ferreira LB, McCluskey PJ, Thorne JE, Matthews JM; International Study Group for Systemic Immunomodulatory Drug Treatment of Non‐Infectious Uveitis; Smith JR. Branford JA, et al. Among authors: matthews jm. Br J Ophthalmol. 2024 Nov 1:bjo-2024-326239. doi: 10.1136/bjo-2024-326239. Online ahead of print. Br J Ophthalmol. 2024. PMID: 39472042
Genetic liability estimated from large-scale family data improves genetic prediction, risk score profiling, and gene mapping for major depression.
Dybdahl Krebs M, Georgii Hellberg KL, Lundberg M, Appadurai V, Ohlsson H, Pedersen E, Steinbach J, Matthews J, Border R, LaBianca S, Calle X, Meijsen JJ; iPSYCH Study Consortium,; Ingason A, Buil A, Vilhjálmsson BJ, Flint J, Bacanu SA, Cai N, Dahl A, Zaitlen N, Werge T, Kendler KS, Schork AJ. Dybdahl Krebs M, et al. Among authors: matthews j. Am J Hum Genet. 2024 Oct 22:S0002-9297(24)00369-0. doi: 10.1016/j.ajhg.2024.09.009. Online ahead of print. Am J Hum Genet. 2024. PMID: 39471805
3,081 results